Company to participate in 'AGILE DxRx 2025'
[by Yu, Suin] 정품 슬롯사이트 Soft, an AI-driven medical imaging solutions company, announced its participation in the 'AGILE DxRx 2025' conference, scheduled to take place in Bangkok, Thailand, from April 3 to 5. During the event, the company intends to present the advancements and future vision of its AI-powered integrated thoracic diagnostic solution.
AGILE DxRx 2025 is an international conference dedicated to promoting the global implementation of early detection and treatment for lung cancer and cardiovascular disease. This year's event will highlight international data demonstrating the effectiveness of chest CT in early 정품 슬롯사이트 and mortality rate reduction of the “big three” diseases: lung cancer, cardiovascular disease, and chronic obstructive pulmonary disease (COPD). The central theme of the conference will focus on cost-effective and efficient approaches to implementing screening programs.
At the conference, 정품 슬롯사이트 Soft plans to unveil clinically validated insights into the early detection and intervention of lung cancer through AI-powered thoracic CT analysis. In particular, Jang Ryeong-woo, Clinical Research Lead at 정품 슬롯사이트 Soft, will participate as a featured speaker. His presentation will cover the latest performance output of the company’s 'AVIEW,' the current limitations in early lung cancer screening, strategies for improving existing lung cancer screening systems, and a forward-looking vision that extends beyond screening limited to high-risk populations.
정품 슬롯사이트 Soft's AI-powered software automatically analyzes chest CT images to assist in the early detection of a range of thoracic diseases, including lung cancer. According to the company, this technology enables medical professionals to make faster and more accurate diagnoses, ultimately contributing to improved patient prognosis. Furthermore, the solution is designed to be cost-effective and adaptable to diverse healthcare settings, positioning it as a potential driver of global innovation in the early detection and treatment of lung cancer and related conditions.
"This year's conference theme aligns closely with our flagship product, 'AVIEW LCS Plus,' a 3-in-1 solution for the simultaneous diagnosis and analysis of thoracic diseases," stated Kwak Ji-wan, Director of Product Implementation & Client Solutions at 정품 슬롯사이트 Soft. "The paradigm of early lung cancer diagnosis is shifting from a single disease-centered approach to an integrated lung health evaluation. In this context, AVIEW LCS Plus, which is optimized for integrated analysis, holds significant value both clinically and in shaping global health policy."
On the other hand, 정품 슬롯사이트 Soft recently obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) for an upgraded version of its solution, featuring advanced technology integration, accessibility, security, and stability. In addition, the company has strengthened its foundation for global market entry by simultaneously obtaining European CE certification, as well as compliance certifications for the 'U.S. Health Insurance Portability and Accountability Act (HIPA)' and 'European General Data Protection Regulation (GDPR),' two of the world’s most authoritative certifications in the field of medical AI.